BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia Data Accepted to ENDO 2020 QED
BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301) BioMarin
